Kara L. Vine

Dr. Kara L. Vine

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
LBLisa Belfiore
Lisa Belfiore
DSDarren Saunders
Darren Saunders
MRMarie Ranson
Marie Ranson
KTKristofer J. Thurecht
Kristofer J. Thurecht
GSGert Storm
Gert Storm
KVKara L. Vine
Kara L. Vine

1 May 2009 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KVKara L. Vine
Kara L. Vine
LML. Matesic
L. Matesic
JLJ. M. Locke
J. M. Locke
MRMarie Ranson
Marie Ranson
Danielle SkropetaDanielle Skropeta
Danielle Skropeta
Isatin (1H-indole-2,3-dione) and its derivatives demonstrate a diverse array of biological and pharmacological activities including anticonvulsant, antibacterial, antifungal, antiviral and anticancer properties. This broad spectrum of biochemical targets has been facilitated by the synthetic versatility of isatin, which has allowed the generation of a large number of structurally diverse derivatives including analogues derived from substitution of the aryl ring, and/or derivatisation of the isatin nitrogen and C2/C3 carbonyl moieties. The recent FDA approval of the oxindole sunitinib malate, as a kinase inhibitor for the treatment of advanced renal carcinoma and gastrointestinal stromal tumours, underscores the increasing interest in isatins as a new class of antineoplastic agents. In addition to potent kinase inhibition, the mechanism of action of other isatin derivatives includes the inhibition and/or modulation of proteases, translation initiation, neo-vascularisation and tubulin polymerisation. It was therefore the objective of this review to systematically evaluate the cytotoxic and anticancer properties of various substituted isatins and collate these findings to be used as a guide for future structure-activity relationship and mode of action studies. This is the first review to comprehensively discuss the in vitro and in vivo anticancer activities of isatin and its substituted derivatives.

13 May 2018 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
STSepehr Talebian
Sepehr Talebian
Javad ForoughiJavad Foroughi
Javad Foroughi
SWSamantha J. Wade
Samantha J. Wade
KVKara L. Vine
Kara L. Vine
Alireza Dolatshahi-PirouzAlireza Dolatshahi-Pirouz
Alireza Dolatshahi-Pirouz
GWGordon G. Wallace
Gordon G. Wallace

1 January 2007 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
KVKara L. Vine
Kara L. Vine
JLJulie M Locke
Julie M Locke
MRMarie Ranson
Marie Ranson
KBKirsten Benkendorff
Kirsten Benkendorff
SPStephen Pyne
Stephen Pyne
JBJohn B Bremner
John B Bremner

21 September 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KVKara L. Vine
Kara L. Vine
JLJulie M. Locke
Julie M. Locke
MRMarie Ranson
Marie Ranson
SPStephen Pyne
Stephen Pyne
JBJohn B. Bremner
John B. Bremner

1 October 2015 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
DBDaniel Brungs
Daniel Brungs
MAMorteza Aghmesheh
Morteza Aghmesheh
KVKara L. Vine
Kara L. Vine
Therese BeckerTherese Becker
Therese Becker
MCMartin G. Carolan
Martin G. Carolan
MRMarie Ranson
Marie Ranson